A5010636107- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- MicroRNA in disease regulation
- Bladder and Urothelial Cancer Treatments
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
- Cholesterol and Lipid Metabolism
- Urinary Tract Infections Management
- Cytokine Signaling Pathways and Interactions
- Plant biochemistry and biosynthesis
- Pediatric Urology and Nephrology Studies
- Ureteral procedures and complications
- Ferroptosis and cancer prognosis
- Urinary Bladder and Prostate Research
- Pelvic floor disorders treatments
- CAR-T cell therapy research
- Renal and Vascular Pathologies
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
University of Würzburg
2016-2025
Universitätsklinikum Würzburg
2014-2025
European Neuroendocrine Tumor Society
2020-2025
German Society of Surgery
2025
Klinik und Poliklinik für Urologie
2014-2023
Klinikum Magdeburg
2023
Jena University Hospital
2023
University Hospital of Bern
2014
Comprehensive Cancer Center Mainfranken
2014
A lack of reliably informative biomarkers to distinguish indolent and lethal prostate cancer is one reason this disease overtreated. miR-221 has been suggested as a biomarker in high-risk cancer, but there insufficient evidence its potential utility. Here we report that an independent predictor for cancer-related death, extending validating earlier findings. By mechanistic investigations showed regulates cell growth, invasiveness, apoptosis at least partially via STAT1/STAT3-mediated...
Abstract Prostate cancer (PCa) shows strong dependence on the androgen receptor (AR) pathway. Here, we show that squalene epoxidase (SQLE), an enzyme of cholesterol biosynthesis pathway, is overexpressed in advanced PCa and its expression correlates with poor survival. SQLE controlled by micro-RNA 205 (miR-205), which significantly downregulated PCa. Restoration miR-205 or competitive inhibition led to de novo biosynthesis. Furthermore, was essential for proliferation AR-positive cell lines,...
To report the long-term outcomes of ileal ureteric replacement (IUR) in complex reconstruction urinary tract.From 1991 to 2016, IUR was performed 157 patients with structural or functional loss. In 52 patients, bilateral became necessary. Implantation sites where either native bladder (n = 79) intestinal reservoirs 78). latter group, technique used at time primary diversion 34), a secondary approach 29), and undiversion conversion procedures 15). Anti-refluxive implantation 37 patients....
Oncogene activation and loss of tumor suppressor function changes the metabolic activity cancer cells to drive unrestricted proliferation. Moreover, adapt their metabolism sustain growth survival when access oxygen nutrients is restricted, such as in poorly vascularized areas. We show here that p53-deficient colon exposed tumor-like stress spheroid culture activated mevalonate pathway promote synthesis ubiquinone. This was essential maintain mitochondrial electron transport for respiration...
Downregulation of miR-221-3p expression in prostate cancer (PCa) predicted overall and cancer-specific survival high-risk PCa patients. Apart from PCa, levels a response to tyrosine kinase inhibitors (TKI) clear cell renal carcinoma (ccRCC) Since this role was explained with specific targeting VEGFR2, we examined whether regulated VEGFR2 PCa. First, confirmed VEGFR2/KDR as target gene cells by applying Luciferase reporter assays Western blotting experiments. Although mainly downregulated the...
Despite latest advances in prostate cancer (PCa) therapy, PCa remains the third-leading cause of cancer-related death European men. Dysregulation microRNAs (miRNAs), small non-coding RNA molecules with gene expression regulatory function, has been reported all types epithelial and haematological cancers. In particular, miR-221-5p alterations have PCa. miRNA data was retrieved from a comprehensive publicly available dataset 218 patients (GSE21036) levels were analysed. The functional role...
Background: Renal cell carcinoma (RCC) is divided into three major histopathologic groups—clear (ccRCC), papillary (pRCC) and chromophobe RCC (chRCC). We performed a comprehensive re-analysis of publicly available datasets from the TCGA (The Cancer Genome Atlas) database, thereby combining samples all subgroups, for an exploratory transcriptome profiling subgroups. Materials Methods: used FPKM (fragments per kilobase million) files derived ccRCC, pRCC chRCC cohorts representing...
Robust biomarkers to predict response immune checkpoint blockade (ICB) in metastatic urothelial carcinoma (mUC) are still demand. Recently, early C-reactive protein (CRP) kinetics and especially the novel CRP flare-response phenomenon has been associated with immunotherapy response.We conducted a multicentre observational study comprising 154 patients mUC treated ICB evaluate predictive value of previously described on-treatment kinetics: flare responders (at least doubling baseline within...
The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. identification predictive moleculobiological markers allowing risk assessment lymph node metastasis and systemic progression essential in establishing effective treatment. In the current study, we investigate prognostic potential miR-205 HRPCa study validation cohorts, setting defined clinical endpoints both. We demonstrate to be significantly down-regulated over 70% samples analysed that...
Introduction: Renal cancer is among the ten most common cancers in western societies, with renal cell carcinoma (RCC) accounting for 95% of malignant neoplasms. Recent advances surgical techniques and approaches have expanded treatment options, necessitating an evaluation optimal approaches. Methods: A retrospective, propensity-matched cohort 814 patients (1999-2021) was conducted comparing open minimally invasive (laparoscopic robotic-assisted) nephrectomy partial techniques, focusing on...
Clear cell renal carcinoma (ccRCC) characterized by a tumor thrombus (TT) extending into the inferior vena cava (IVC) generally indicates poor prognosis. Nevertheless, risk for recurrence after nephrectomy and thrombectomy varies. An applicable accurate prediction system to select ccRCC patients with TT of IVC (ccRCC/TT) at high is urgently needed, but has not been established up now. To our knowledge, possible role microRNAs (miRs) development ccRCC/TT or their impact as prognostic markers...
Metformin (MF) acts as a tumour-suppressor in renal cell carcinoma (RCC) by inhibiting the AKT/mTOR pathway via AMPK activation. Here, we explore influence of miR-21 and its target gene PTEN on MF effects CAKI-1 CAKI-2 cells.Proliferation assays (MTS) qRT-PCR after transient transfection with pre- anti-miR-21 treatment were conducted. AMPK-dependency was assessed siAMPK. The expression PTEN, AKT pre-miR-21 analysed.We demonstrate that cells, which found to be less sensitive towards MF,...
Die Therapie des Nierenzellkarzinoms (RCC) ist stark stadienabhängig und umfasst chirurgische Ansätze, Systemtherapien palliative Maßnahmen. Beim lokalisierten RCC steht die kurative operative Entfernung im Fokus, während in metastasierten Stadien eine Kombination aus Immun- Tyrosinkinase-Inhibitoren sowie individuelle Interventionen erfordern. adjuvante mit Checkpoint-Inhibitoren verbessert Prognose bei Hochrisikopatienten signifikant. orientieren sich an Prognosekriterien wie den...
Immune checkpoint blockade (IO) has revolutionised the treatment of metastatic renal cell carcinoma (mRCC). Early C-reactive protein (CRP) kinetics, especially recently introduced CRP flare-response phenomenon, shown promising results to predict IO efficacy in mRCC, but only been studied second line or later. Here, we aimed validate predictive value early kinetics for 1st-line mRCC with αPD-1 plus either αCTLA-4 (IO+IO) tyrosine kinase inhibitor (IO+TKI).In this multicentre retrospective...
Expression of circulating serum microRNAs has not been studied in a cohort patients with papillary renal cell carcinoma (pRCC) so far. We hypothesized that miRNA deregulation malignant tissue is reflected and could be used for non-invasive diagnosis pRCC as well differentiation between type 1 2 pRCC.We selected 11 differentially regulated miRNAs from the Cancer Genome Atlas (TCGA) data set potential validation candidates. Serum expression was determined by qRT-PCR total 34 1, 33 control...
(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools PSMA-TV TL-PSMA produce comparable results. (2) Methods: 68Ga-PSMA n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified our single-centre database. calculated Syngo.via...
We investigated the long-term oncological and functional outcome of nephron-sparing surgery/partial nephrectomy (PN) versus radical (RN) for any renal cell carcinoma (RCC) ≥4 cm.Between 1997 2013, we identified 128 patients undergoing PN RCC cm matched this collective to RN. then compared overall survival (OS), cancer-specific (CSS), progression-free (PFS) parameters in both groups. The median follow-up time was 58 months (3-210 months).Compared RN, with a showed significantly higher 10-year...
(1) Background: Clear cell renal carcinoma extending into the inferior vena cava (ccRCCIVC) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed microRNA(miR)-based risk classifier-containing miR-21-5p, miR-126-3p and miR-221-3p expression-which significantly predicted cancer-specific (CSS) ccRCCIVC patients. (2) Methods: Examining single-center cohort tumor...
Although biomarkers predicting therapy response in first-line metastatic renal carcinoma (mRCC) remain to be defined, C-reactive protein (CRP) kinetics have recently been associated with immunotherapy (IO) response. Here, we aimed assess the predictive and prognostic power of two contemporary CRP definitions a large, real-world mRCC cohort.Metastatic patients treated IO-based within 5 years were retrospectively included this multicentre study. According Fukuda et al., defined as 'CRP...